SUMMARY PARAGRAPH
Fanconi anemia (FA) is a monogenic inherited disease associated with mutations in genes that encode for proteins participating in the FA/BRCA DNA repair pathway. Mutations in FA genes result in chromosomal instability and cell death, leading to cancer risks and progressive cell mortality, most notably in hematopoietic stem and progenitor cells (HSPC). Recently, we showed the first clinical evidence that gene therapy confers engraftment and proliferative advantage of gene-corrected HSPCs in FA patients1. Despite this and many other gene therapy advances, the question of whether the molecular pathways affected in monogenic diseases can be reverted by lentiviral-mediated gene therapy has never been addressed. This is even more challenging in DNA repair syndromes such as FA since in these cases, transcriptional defects in affected cells might not be restored due to DNA damage accumulated prior to gene therapy. Using single-cell RNA sequencing in HSPCs from FA-A patients previously treated by ex vivo gene therapy, we demonstrate that lentiviral-mediated gene therapy prior to severe bone marrow failure not only restores the expression of the defective gene, but also induces a long-term correction of the transcriptional program in FA HSPCs, which then acquire a signature characteristic of healthy HSPCs. Our results reveal new molecular evidence showing the potential of gene therapy to fully rescue phenotypic defects in FA, a devastating HSPC disease characterized by defective DNA repair.
Competing Interest Statement
The Hematopoietic Innovative Therapies Division at CIEMAT receives funding and has licensed the PGK-FANCA-WPRE* lentiviral vector to Rocket Pharmaceuticals. J.A.B. and J.S. are consultants for Rocket Pharmaceuticals. J.D.S. is an employee of Rocket Pharmaceuticals. P.R., S.N., J.S and J.A.B. are inventors on patents filed by CIEMAT, CIBERER and Fundacion Jimenez Diaz, and may be entitled to receive financial benefits from the licensing of such patents.
Funding Statement
This work was supported by grants from the European Commissions Seventh Framework Program (HEALTH-F5-2012-305421) to the EUROFANCOLEN Consortium J.B. and J.Se; from Ministerio de Economia, Comercio y Competitividad and Fondo Europeo de Desarrollo Regional (RTI2018-097125-B-I00 to P.R. and S.N.); from Gobierno de Navarra, Departamento de Desarrollo Economico y Empresarial (AGATA 0011-1411-2020-000010); from Instituto de Salud Carlos III (ISCIII) and co-financed by FEDER CIBERONC (CB16/12/00489 and CB16/12/00225); Redes de Investigacion Cooperativa (TERCEL RD16/0011/0005) and from Consejeria de Educacion, Juventud y Deporte de la Comunidad de Madrid (AvanCell Project; B2017/BMD3692). M.A. was supported by a PhD Fellowship from Ministerio de Ciencia, Innovacion y Universidades (FPU18/05488). CIBERER and CIBERONC are initiatives of the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the clinical research ethics committee of Clinica Universidad de Navarra.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors declare that the data supporting the findings of this study will be made available before the manuscript publication. Also data will be made available upon request, and following GDPR guidelines, after peer-review publication.